Want to see ENSC full AI Analyst Report?
ENSC Stock Chart & Stats
$0.40
<$0.01(0.08%)
At close: 4:00 PM EDT
$0.40
<$0.01(0.08%)
Day’s Range― - ―
52-Week Range$0.23 - $2.75
Previous CloseN/A
Volume225.00K
Average Volume (3M)89.63K
Market Cap
$7.78M
Enterprise Value$2.97
Total Cash (Recent Filing)$676.70K
Total Debt (Recent Filing)$196.84K
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.76
Shares Outstanding19,456,795
10 Day Avg. Volume106,568
30 Day Avg. Volume89,627
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.73
Price to Sales (P/S)0.00
P/FCF Ratio-0.30
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.27
Revenue Forecast (FY)$7.30M
Bulls Say, Bears Say
Bulls Say
Abuse-deterrent PlatformThe TAAP and MPAR platforms address persistent opioid-safety needs by combining analgesia with barriers to tampering and high-dose misuse, potentially supporting differentiated products and partnerships if clinical development succeeds.
Pipeline ExpansionAdding CY-200 broadens Ensysce beyond abuse-deterrent opioids into a designated rare-disease program, increasing pipeline diversification and creating a potentially clearer regulatory pathway for a focused pain indication.
Development FinancingThe completed initial financing provides capital to advance the expanded pain pipeline, while the milestone-based tranche could support CY-200 through Phase 2 and later development if clinical objectives are achieved.
Bears Say
Persistent Large LossesLosses remain many times larger than reported revenue, showing that development and corporate costs substantially exceed current commercial activity and leaving limited evidence of operating leverage or near-term self-sufficiency.
Ongoing Cash BurnSustained negative operating and free cash flow means Ensysce must continue funding research and operations externally, creating recurring financing requirements and exposing shareholders to potential dilution over the development cycle.
Listing And Capital RiskAlthough equity-rule compliance was temporarily regained, continued bid-price and initial-listing requirements create a material structural risk; failure could lead to suspension, restrict financing access, and disrupt development plans.
Ensysce Biosciences News
ENSC FAQ
What was Ensysce Biosciences’s price range in the past 12 months?
Ensysce Biosciences lowest stock price was $0.23 and its highest was $2.75 in the past 12 months.
What is Ensysce Biosciences’s market cap?
Ensysce Biosciences’s market cap is $7.78M.
When is Ensysce Biosciences’s upcoming earnings report date?
Ensysce Biosciences’s upcoming earnings report date is Nov 16, 2026 which is in 76 days.
How were Ensysce Biosciences’s earnings last quarter?
Ensysce Biosciences released its earnings results on Aug 19, 2026. The company reported -$0.2 earnings per share for the quarter.
Is Ensysce Biosciences overvalued?
According to Wall Street analysts Ensysce Biosciences’s price is currently Overvalued.
Does Ensysce Biosciences pay dividends?
Ensysce Biosciences does not currently pay dividends.
What is Ensysce Biosciences’s EPS estimate?
Ensysce Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ensysce Biosciences have?
Ensysce Biosciences has 19,456,795 shares outstanding.
What happened to Ensysce Biosciences’s price movement after its last earnings report?
Ensysce Biosciences reported an EPS of -$0.2 in its last earnings report. Following the earnings report the stock price went up 0.779%.
Which hedge fund is a major shareholder of Ensysce Biosciences?
Currently, no hedge funds are holding shares in ENSC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ensysce Biosciences
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Technical Analysis
Ownership Overview
4.71% Insiders
0.17% Mutual Funds
1.30% Other Institutional Investors
93.75% Public Companies and
Individual Investors